Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Kidney cancer

N J Vogelzang1, W M Stadler

  • 1University of Chicago Medical Center, Section of Hematology/Oncology, IL 60637-1470, USA. njvogelz@mcis.bsd.uchicago.edu

Lancet (London, England)
|December 16, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).

BMC cancer·2021
Same author

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421.

Cancer treatment and research communications·2019
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Kidney cancer incidence is rising, particularly in older men. Current treatments for metastatic kidney cancer are limited, but new therapies are under investigation.

Area of Science:

  • Oncology
  • Urology

Background:

  • Kidney cancer incidence has risen significantly in the USA since 1973.
  • Risk factors include male gender and increasing age.
  • The von Hippel-Lindau tumor suppressor gene is frequently inactivated in sporadic cases.

Purpose of the Study:

  • To review current understanding and treatment of kidney cancer.
  • To highlight challenges in managing metastatic disease.
  • To discuss emerging therapeutic strategies.

Main Methods:

  • Literature review of kidney cancer epidemiology and treatment.
  • Analysis of current therapeutic options for early-stage and metastatic disease.
  • Overview of ongoing clinical investigations.

Main Results:

Related Experiment Videos

  • Early-stage kidney cancer is managed with nephrectomy.
  • Metastatic disease is present in 20-30% of patients at diagnosis.
  • Interleukin-2 offers limited long-term survival for metastatic cases (5-8%).

Conclusions:

  • Therapy for metastatic renal cancer remains challenging.
  • Surgical intervention for localized metastases and thrombus is crucial.
  • Active research into novel agents like anti-angiogenesis drugs offers future hope.